• StorEn issued ANYSeed a convertible note in 2019; the fund recently converted the note into equity
• ANYSeed supports science and technology-based, early-stage ventures located in downstate New York
• Focused on offering innovative battery storage, StorEn Technologies is leading way in the development of evolutionary vanadium flow batteries

StorEn Technologies, a developer of evolutionary vanadium flow batteries with a disruptive patent-pending, all-vanadium flow battery technology, has announced that Accelerate New York Seed Fund (ANYSeed) has become a shareholder (https://ibn.fm/vJewK). “Over three years ago, in March of 2019, we raised funds from ANYSeed and issued them a convertible note after receiving the financing,” StorEn announced. “If you’re not familiar with how convertible notes work, they are a popular fundraising instrument, a hybrid of debt and equity. They are structured as loans with the option of converting to equity, as opposed to requesting the repayment of the principal plus accrued interest. “We’re so grateful to ANYSeed for converting their note into equity,” the announcement continued. “Thank you for supporting our enduring progress in the path to volume manufacturing. . . . With the help of all our shareholders, like ANYSeed, we are striving to make StorEn a success.” In partnership with Empire State Development, the Accelerate NY Seed Fund supports science and technology-based, early-stage ventures located in downstate New York (https://ibn.fm/OD9ps). The fund’s mission is to facilitate the transition from laboratory research and ideas into products, processes and services that deliver a financial return to investors. The fund considers projects in the biopharma, materials, tech, med tech, healthcare and energy sectors, with a strong preference for research institution affiliation and intellectual property strength. With its strong tie to Stony Brook University in New York, StorEn Technologies fits the bill perfectly. Focused on offering innovative battery storage for the 21st century, StorEn Technologies is leading the way forward in the development of evolutionary vanadium flow batteries. The battery pioneer is currently in the middle of a Reg A offering, creating a unique opportunity for investors interested in the future of battery storage. StorEn is currently in the process of a RegA offering with four different investment tiers; each tier offers a different discount and reward (https://ibn.fm/E4IcJ). With a proprietary product that answers the call for long-lasting, 100% recyclable, safe and affordable energy storage, StorEn and its disruptive, patent-pending, all-vanadium flow battery technology for energy storage holds real promise in a growing market. The company has developed evolutionary vanadium flow batteries. Incubated at the Clean Energy Business Incubator Program (“CEBIP”) within Stony Brook University in New York, the company is building upon the strengths of vanadium flow batteries to revolutionize the world of residential and industrial energy storage. In part, StorEn’s technology has enhanced the electrical efficiency of the stack and energy density of the electrolyte and module, ultimately reducing costs and improving performance. The company produces products with a battery life of 25 years and more than 15K cycles. That company takes pride in offering batteries that meet consumers demand for efficient, durable and cost-effective energy storage, enabling self-consumption of self-produced electricity and the transition toward a carbon-free economy. For more information, visit the company’s website at www.StorEn.tech. NOTE TO INVESTORS: The latest news and updates relating to StorEn Technologies are available in the company’s newsroom at https://ibn.fm/StorEn

• Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
• The company recently revealed its participation at the annual H.C. Wainwright Global Investment Conference, held between September 13-15, 2021
• Through its sugarBEAT flagship product, Nemaura has sought to capitalize on the expanding Type 2 Diabetes market, expected to reach an annual value of $59 billion by 2025

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs; the company’s flagship product, the sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor designed to help people with diabetes and prediabetes manage their glucose levels. Nemaura Medical’s management recently revealed their attendance at the 23rd Annual H.C. Wainwright Global Investment Conference, held in an entirely digital forum between September 13-15, 2021 (https://ibn.fm/1OiBy). Initially founded in 1868, H.C. Wainwright is a U.S.-based investment bank offering leading-edge investment banking, corporate finance, and strategic advisory services to public and private growth companies across multiple sectors and regions. The 23rd Annual H.C. Wainwright Global Investment Conference (https://ibn.fm/x6vUI) featured over 850 corporates in attendance, distributed across six distinctive sector tracks, namely – healthcare & life sciences; metals & mining; cryptocurrency, blockchain, & fintech; cleantech; technology, media & telecommunications; as well as shipping & maritime. In addition, the conference featured some of the industry’s leading keynote speakers, one-on-one investor meetings, and networking opportunities with attendees. H.C. Wainwright’s annual investment conference routinely attracts some of North America’s largest institutional investors, private equity firms, and venture capitalists seeking new investment opportunities. Over 420 million people globally are currently living with diabetes, with prediabetic cases totalling almost three times that number. In the US alone, over $760 billion was spent on diabetes-related health care expenditures during 2019, equating to an average annual spend upwards of $9,000 per diabetic patient compared to approximately $1,600 for a healthy individual (https://ibn.fm/Fzjhi). Combining clinical research with patient-friendly technology and through its sugarBEAT product, Nemaura Medical seeks to provide a non-invasive, affordable, and flexible method of blood glucose tracking for improved diabetes management. NMRD has positioned itself at the intersection of the global Type 2 diabetes market, which is expected to reach an annual value of nearly $59 billion by 2025. Moreover, the product also allows the company to participate in the $50-plus billion prediabetic market and the wearable health-tech sector for weight loss and wellness applications, which is forecast to hit $60 billion by 2023. For more information, visit the company’s website at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• WHO survey reports that mental health services in 93% of countries around the world have been disrupted or halted as a result of COVID-19
• People with pre-existing mental, neurological or substance-use disorders are more vulnerable to SARS-CoV-2 infection
• Cybin is on a mission to revolutionize mental healthcare

A World Health Organization (“WHO”) survey covering 130 countries is calling attention to the fact that today’s demand for mental health, which has been rocked by the COVID-19 pandemic, is only increasing (https://ibn.fm/hzmXq). Cybin (NEO: CYBN) (NYSE American: CYBN) is focused on meeting that need and is committed to finding even more effective ways to help those struggling with mental health issues. “The COVID-19 pandemic has disrupted or halted critical mental health services in 93% of countries worldwide while the demand for mental health is increasing, according to a new WHO survey,” a WHO news release reported. “The survey of 130 countries provides the first global data showing the devastating impact of COVID-19 on access to mental health services and underscores the urgent need for increased funding.” The release goes on to note that the underfunding of mental health issues is nothing new. “Prior to the pandemic, countries were spending less than 2% of their national health budgets on mental health, and struggling to meet their populations’ needs,” the release pointed out. “And the pandemic is increasing demand for mental health services. Bereavement, isolation, loss of income and fear are triggering mental health conditions or exacerbating existing ones. “Many people may be facing increased levels of alcohol and drug use, insomnia, and anxiety. Meanwhile, COVID-19 itself can lead to neurological and mental complications, such as delirium, agitation, and stroke. People with pre-existing mental, neurological or substance use disorders are also more vulnerable to SARS-CoV-2 infection — they may stand a higher risk of severe outcomes and even death.” The report quotes the director-general of WHO, Dr. Tedros Adhanom Ghebreyesus. “Good mental health is absolutely fundamental to overall health and well-being. COVID-19 has interrupted essential mental health services around the world just when they’re needed most. World leaders must move fast and decisively to invest more in life-saving mental health programs — during the pandemic and beyond.” The survey only underscores the work that Cybin is doing. This game-changing company is keenly aware that more than 700 million people around the world are impacted with some sort of mental illness, addiction or eating disorder, and the company is on a mission to revolutionize mental healthcare. The innovative organization is focused on leveraging its expertise in the psychedelic therapeutic space to deliver proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. “We are focused on addressing the mental health crisis and transforming the treatment landscape,” the company’s website states. “To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients.” For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• StraightUp Resources is a mineral property acquisition and exploration company currently focused on potential production targets in Ontario, Canada’s historic Red Lake Mining District
• StraightUp has options to four flagship properties that together comprise over 20,000 hectares (about 50,000 acres) in a region that has produced more than 30 million ounces of gold historically
• The company announced this month that it has completed a high-resolution heli-borne magnetic survey (“MAG”) on its largest project that will help the company decide where potential gold mineralization worth further exploration may lie
• The company’s efforts to fund its exploration work include a recently announced private placement offering and an initial financing tranche closing that raised C$301,100

Mineral explorer and acquisition company StraightUp Resources (CSE: ST) is making inroads on the evaluation of potential yields from flagship properties it has acquired options to in the well-known rich gold resource district within Ontario, Canada. StraightUp announced earlier this month that it had completed a high-resolution heli-borne magnetic survey (“MAG”) on the RLX North and RLX South properties that comprise the company’s largest area of operation currently — claims covering over 10,000 hectares (about 25,000 acres). The MAG survey consists of 2,985 line-km at 50-meter line intervals covering the entire property and the results will be used to help determine areas of potential gold mineralization and high-merit areas worthy of further exploration. “It is exciting to see how the adoption of technology has led to such advanced interpretation and with computer modelling, revolutionization of the industry,” StraightUp President and CEO Mark Brezer stated in a news release announcing the project’s status (https://ibn.fm/M3M5Z). “These projects are in the heart of the Red Lake Mining District, an area that is seeing a resurgence of gold bearing deposits that were overlooked in the past. RLX North and South almost completely surround Great Bear Resources Sobel Project and with our accumulated data from the region and upcoming MAG results, we can better pin-point future drill programs.” The Red Lake district is renowned for over 30 million ounces of historic gold production, and the RLX projects are situated near the Red Lake Mine complex that is the district’s largest gold deposit with estimated reserves of 3.23 million ounces as of a 2019 report (https://ibn.fm/qQtLi). The company regards the contact between the metavolcanic packages of north and south RLX properties as “highly prospective” for economic deposits of gold, or deposits that are formed in such a way that they can be mined out of economic interests. Most of the ore production that has taken place in the district historically has come from within a few hundred meters of the contact point, according to the company. The RLX properties are joined by other neighboring projects StraightUp has optioned, including the 6,600-hectare (16,308-acre) Ferdinand Gold Property, the 2,000-hectare (4,942-acre) Belanger property and the 1,944-hectare (4,803-acre) Bear Head Gold Project, which extend into a neighboring greenstone belt. As StraightUp evaluates the prospects of the properties, it continues to acquire financing for the projects. Concurrent with the announcement of completing the RLX MAG survey, the company announced a non-brokered financing to raise up to C$2 million through a private placement offering and the close of the first tranche of the financing, raising C$301,100 by issuing 1.5 million common shares and 752,750 warrants. The private placement offers one common share at a price of C$0.20 and one-half of a transferable common share purchase warrant, which can be used to buy an additional common share at a price of C$0.30 per whole warrant. The net proceeds will be used to fund upcoming exploration projects and other property expenditures. In June, the company received preliminary MAG survey results from its Ferdinand Gold Project and began ground work exploration there in August (https://ibn.fm/28CmC). In June the company also filed an NI 43-101 compliant technical report that recommends further exploration on the Belanger Property (https://ibn.fm/2de7C). For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to ST are available in the company’s newsroom at https://ibn.fm/STR

• Delic has positioned itself as a leading psychedelic wellness platform, with businesses spanning all corners within the sector
• Delic’s latest announced acquisition will make it the largest chain of operating psychedelic wellness clinics in the US
• The psychedelic wellness sector has enjoyed robust growth as of late, following the FDA’s move towards granting psilocybin “breakthrough therapy” status in 2018
• Denver and Oakland have been among the first US cities to decriminalize the use of psilocybin mushrooms with California currently studying whether to follow suit
• The psychedelic drugs market is expected to reach a size of $10.75 billion by 2027

When Michael Pollard embarked on writing his seminal book, How to Change Your Mind in 2018, the psychedelic wellness industry was a far different world to what we know today (https://ibn.fm/SiWdt). Although the psychedelic industry boasts a long history in America dating back to the 1950s, it’s only in the last few years that scientific research into the world of psychedelics and its related compounds has uncovered their potential to relieve a wide array of mental suffering, including depression, anxiety, and addiction. Delic Holdings (CSE: DELC) (OTCQB: DELCF) has sought to capitalize on the ongoing transformation within the sector, positioning itself as the leading psychedelic wellness platform committed to bringing science-backed benefits to all and reframing the psychedelic conversation. Originally formed in 2019 to address the growing interest within the science-backed psychedelic wellness sector, Delic has transformed itself into a sprawling conglomerate with services spanning all areas within the sector. The company’s related businesses now include trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers and Ketamine Wellness Centers (pending acquisition), making it the largest psychedelic wellness clinic chain in the country. According to the National Institute of Mental Health, over 17 million Americans have at least one major depressive episode every year, and up to 30 percent of them receive insufficient help from current medical treatments. Meanwhile, a further estimated 40 million adults struggle with anxiety disorders. In a move towards addressing the growing health crisis in 2018, the FDA moved towards granting psilocybin “breakthrough therapy” status for the treatment of severe depression. Shortly thereafter, first Denver and then Oakland voted to decriminalize the use of psilocybin mushrooms, with the state of California currently reviewing a bill to decriminalize a wide variety of psychedelics (https://ibn.fm/SV0LT). With the sector on the cusp of broad-based legalization, the psychedelic drugs market is now projected to grow to a size of $10.75 billion by 2027, up from $4.75 billion in 2020 with a forecast CAGR of 12.36 percent over the period of 2021-2027 (https://ibn.fm/sqQwO). Delic has responded by servicing the growing interest within the sector through the expansion of its wide-ranging media business, which includes the provision of a free education platform; hosting Meet Delic, the first-ever psychedelic wellness summit; and the creation of Delic Radio — a station featuring over 43 podcast episodes delving into different aspects of the psychedelic industry. Simultaneously and in line with their goal of enabling billions of people to live happier lives through the provision of psychedelic treatments, Delic has acquired Ketamine Infusion Centers, which operates two ketamine clinics located in Bakersfield, California, and Phoenix, Arizona, and recently announced its acquisition of Ketamine Wellness Centers, which currently operates 10 clinics across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas and Washington. Delic expects to open 15 additional clinics across the country over the next 18 months. In recognition of the rapidly changing state of the industry, Delic has also focused its efforts around Delic Labs, a licensed cannabis and psilocybin research laboratory. It is the only Health Canada-licensed entity to exclusively focus on research and development of psilocybin vaporization technology. The psychedelic wellness industry has long been recognized as one of the fastest growing segments within the global healthcare industry. With its business spanning all aspects of the sector, Delic looks optimally positioned to benefit from the continued growth in the sector and the ongoing legalization efforts around the world. For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• Up to 50% of cancer is preventable, while other types can be detected or treated early, often resulting in complete remission for patients
• AnPac Bio-Medical Science Co., Ltd. uses blood-based testing to detect many types of cancer (multi-cancer tests) and pre-cancer diseases, predicting its potential to occur in the future
• Company’s proprietary CDA technology is powered by a database of over 220,000 clinical and general population test samples and cases and leverages a proprietary algorithm to generate personalized cancer screening
• Its follow-up study on multi-cancer risk assessment tests is believed to be the largest on-going study which has demonstrated its effectiveness with significant amount of confirmed cases of over 20 cancer types, over 20 pre-cancer diseases and major diseases at the hospitals

Cancer is the second leading cause of death worldwide, claiming approximately 10 million lives per year, which equals approximately one in six of all annual deaths. With the proper screening and detection methods, as well as healthy lifestyle choices including public health measures like immunizations against infections that could cause cancer, the World Health Organization (“WHO”) estimates that up to 50% of cancers could be prevented. Many of the cancers that are not preventable can be detected early, treated, and cured – sending the patient into remission (https://ibn.fm/sYvxk). But cancers are frequently not caught by general practitioners, missed because the symptoms are overlooked or attributed to something else. The results can be deadly, with cancers being detected at a dangerously late stage. AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on cancer screening and early detection, has developed a proprietary approach to detect cancerous and pre-cancerous diseases – Cancer Differentiation Analysis (“CDA”) technology. CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. CDA platform, in which CDA technology is combined with protein based biomarker tests to obtain even more comprehensive information, can be used to obtain more comprehensive data and information. Unlike most liquid-based cancer screening and detection methods, CDA platform from AnPac Bio focuses on assessing the existing protein based biomarkers with biophysical properties of the blood tested to signal the lead-up to serious health problems, including cancer, which has been used to help assessing cancer risk and its type, and predict where the risk is highest in the future through a standard blood test. CDA is powered by a database of over 220,000 samples and cases, allowing it to serve as a new approach to disease and cancer screening. AnPac Bio’s technology leverages a proprietary algorithm that synthesizes the data, effectively generating a personalized assessment approach for general population. Through CDA and CDA platform, AnPac Bio aims to fulfill numerous goals, including:

• Innovate: In the cancer screening industry, AnPac Bio is an innovator. CDA research has been ongoing since 2008, with commercial operations commencing in 2015. The company considers itself a thought leader in developing multi-cancer screening
• Detect: AnPac Bio is passionate about the early detection of signals of life-threatening cancers
• Identify: AnPac Bio’s CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity
• Provide: AnPac Bio’s platform provides a multi-level and multi-parameter analysis with proprietary algorithmic assessment, resulting in accurate and easy-to-understand results
• Prove: Using the analysis of database consisting of over 220,000 samples, AnPac Bio and its CDA technology have been proven to identify individuals with pre- and early-stage cancer in general population that were previously assessed “cancer-free” through more conventional testing methods
• Biophysical Properties: CDA focuses on analyzing biophysical properties of human blood samples and correlates them to biophysical properties and cancer occurrence

AnPac Bio is thus uniquely positioned to disrupt the global cancer diagnostics market, which is expected to reach $249.6 billion by 2026, growing at a CAGR of 7% during the forecast period (https://ibn.fm/0Nt7e). The rapid growth in the industry can be attributed to the increased need for early detection and screening methods, which AnPac Bio and its proprietary technology offer. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

• Cannabis-delivery acquisitions increasing as companies want in on explosive growth of e-commerce cannabis sales
• CEO announces newly acquired property will serve as location of new SGMD Nug Avenue delivery hub
• Sugarmade signed MOU for licenses to serve as essential piece of plan to open three cannabis-related commercial operations in California

Amid growing interest and acquisition activity in California’s direct-to-consumer cannabis delivery sector, Sugarmade (OTC: SGMD) has closed on its most recent acquisition, a parcel of prime property in Los Angeles, which it plans to use as a new distribution/delivery hub for its Nug Avenue cannabis delivery segment (https://ibn.fm/4jB0F). “The explosive growth of e-commerce during the COVID-19 pandemic has propelled new interest in acquisitions involving direct-to-consumer cannabis delivery,” reported a recent MJBizDaily article (https://ibn.fm/XCG1q). “Some marijuana companies have acquired delivery-only cannabis dispensaries, while others have spent more to acquire vertically integrated MJ firms with home-delivery operations included. The article noted that companies involved in recent delivery-related acquisitions have said that the deals help them quickly access an existing base of loyal delivery customers, gain delivery expertise to apply to their existing operations and leverage delivery assets in other U.S. markets. “I think these M&A transactions are a part of a bigger phenomenon, which is the growth of delivery. It’s one way to achieve that – you acquire it,” the article quoted investment banker Frank Columbo as saying. Columbo is director of data analytics at Viridian Capital Advisors, which tracks capital raises, mergers and acquisitions in the cannabis sector. “We are very excited to announce the upcoming location of our new Nug Avenue delivery hub, which is in a prime position to serve the downtown LA area,” said Sugarmade CEO Jimmy Chan. “Our initial Nug Avenue location has been open for nearly six months and has established a strong brand with tremendous growth in membership — already exceeding 10,000 members and growing fast. Our remaining licenses can be applied to both expansion and verticalization of Nug Avenue operations as we continue to build a top-tier, farm-to-door leader in the California cannabis marketplace.” Prior to closing on the acquisition of the LA property, Sugarmade signed a memorandum of understanding to obtain three nonstorefront California cannabis licenses from the Los Angeles Department of Cannabis Regulation, along with corresponding licenses from the California Bureau of Cannabis Control. Combined, these licenses provide an essential piece of SGMD’s strategic plan to open three new cannabis-related commercial operations in California. According to the announcement, the Company intends to use one of the licenses, once obtained, to this newly acquired property in LA; the company will designate it as a licensed cannabis delivery business under its Nug Avenue brand. Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. In addition to its financial interest in the BudCars brand, SGMD’s brand portfolio includes Nug Avenue, CarryOutsupplies.com, SugarRush(TM), Lemon Glow and BudCars. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD

• One of the main challenges with drug delivery and the overall effectiveness of the drugs is first-pass metabolism/excretion
• Lexaria solves this problem with its DehydraTECH(TM) drug delivery technology
• Since the company began working on this technology back in 2014, it has made major strides in the delivery of hypertension and anti-viral treatments

Since its inception, Lexaria Bioscience (NASDAQ: LEXX) has remained committed to enhancing the speed and overall efficiency of orally delivered fat-soluble active molecules in drugs. With its drug delivery technology, DehydraTECH(TM), the company has aided in developing hypertension and anti-viral treatments (https://ibn.fm/96k7t). This is a big achievement for the company and is already making an impact in the pharmaceutical industry. One of the main challenges with drug delivery and the overall effectiveness of the drugs is first-pass metabolism/excretion. Also referred to as the first-pass effect or presystemic metabolism, this is an occurrence where whenever a patient takes a drug orally, it enters the liver and suffers extensive biotransformation to a level where its bioavailability or overall effectiveness is drastically reduced, ultimately showing subtherapeutic action (https://ibn.fm/vfEfN). In the past, scientists and pharmaceutical companies have tried to address this by calculating the total quantity of the metabolized drug, with an equivalent amount of excess drug added to the oral formulation. Alternatively, they have tried to explore alternative routes of drug administration, specifically designed to bypass first-pass metabolism. Of the tried and tested workarounds to the issue, some have shown more promise than others. However, nothing comes close to Lexaria’s DehydraTECH. Since Lexaria began working on this technology in 2014, DehydraTECH has developed considerably and impacted the industry. So far, it has proven useful for potentially treating hypertension, along with the delivery of Colchicine, a drug with known SARS-CoV-2 anti-viral properties (https://ibn.fm/eaBrv). DehydraTECH is applied by incorporating an intermediate step in the formulation and manufacturing of existing or orally ingestible and topical products. This is a crucial step that entails mixing the active ingredients as a delivery “payload” with specific fatty acids and infusing the mixture into a substrate material. The next step involves using a controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level before integrating the newly-combined molecules into end-product production across various dosage form factors. From a commercial standpoint, Lexaria’s technology is proving to offer an additional layer that companies that offer consumer supplements, prescription, and non-prescription-based drugs, cannabis, and nicotine products can use to improve the effectiveness of both new and existing products. With over 50 pending patents in countries worldwide, along with 21 granted patents in countries of highest commercial potential such as the US, the EU, Japan and more, Lexaria understands the value of this technology and its usefulness, both to patients and pharmaceutical companies. Gone are the days of having to calculate the total quantity of the metabolized drug once orally taken. DehydraTECH allows the body to bypass first-pass-liver processing, allowing for smaller doses and effective treatment for specific conditions and ailments. It is a tremendous milestone, not just for Lexaria but also for the medical industry. With what the company has achieved since 2014, it is evident that bigger and better things are to come. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• EMR report projects that North America is likely to be fastest, largest marketplace for cannabis beverages
• Cannabis beverage industry projected to grow at CAGR of 48% in the next five years, reaching an anticipated $12.7 billion by 2026
• BevCanna manufactures its own beverage product lines, offers white-label services to companies looking for the highest-quality products available

North America will be a leader in the global cannabis beverage market, according to a recent Expert Market Research (“EMR”) report (https://ibn.fm/ucsAZ). This projection bodes well for BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health & wellness beverage and natural products company developing and manufacturing a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. “North America is likely to be the fastest and largest marketplace for cannabis beverages,” the EMR report stated. “The legalization of cannabis for medical, therapeutic, and recreational purposes is driving the growth of market. In 2018, Canada legalized the utilization of marijuana for recreational and medical purposes. Various states in the United States have made the addition of cannabis infusion legal in food and beverages. This factor is predicted to spice up the expansion of the cannabis food and beverage market in North America.” EMR went on to note that worldwide, the cannabis beverage industry is expected to grow at a CAGR of 48% in the next five years, reaching an anticipated $12.7 billion by 2026. The report noted that increasing demand for wellness beverages is expected to drive the expansion of cannabis beverages industry. Other drivers behind the market growth include the lower sugar content of the product, the presence of consistently dosed amount of cannabis for consumption, the legalization of marijuana consumption for medical and recreational purposes in many countries, and the growing consumer interest in cannabis edibles. “Cannabis consumers are shifting their interest from smoking cannabis to other ways, like beverages, tinctures, and chocolates, and other edibles,” the report noted. “Consumers are willing to consume concentrated and cannabis-infused products, which successively is anticipated to support the market growth. Cannabis beverages are predicted to exchange other marijuana-infused consumables, like chocolates, cookies, brownies, and confectionaries like gummies and candies which are considered to be not healthy. This factor is predicted to spice up the demand for cannabis drinks over the forecasted period.” Ideally situated in this booming space, BevCanna is in a position to leverage its state-of-the-art facilities and expertise to manufacture its own beverage product lines and to provide white label solutions to a growing list of third-party companies. For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• 5,900 hospitals in the US lack the necessary extensive EEG tech
• BRSF has created a cost-effective solution capable of supplying these hospitals with the equipment needed and broadening the reach of each neurologist
• Emergency departments and hospitals are not the only markets in need of brain monitoring devices, and the industry is expected to grow to $208 billion by 2023

For most U.S. patients, an EEG is mostly unavailable during their journey, from home by EMS to the Emergency department. Additionally, for those patients who are admitted to the ICU, less than 45 percent of ICUs offer EEG monitoring. There are approximately 6,090 hospitals in the U.S., and around 5,900 of them lack the necessary extensive EEG tech coverage. There are several reasons for the lack of access:

• Costs and/or space: 70% of US hospitals do not have the equipment for routine EEGs
• Traditional EEGs require a specialized technician to administer and read the data
• The equipment is bulky, which restricts accessibility and mobility
• Twenty (20) states have less than 10 neurologists per 10,000 patients
• Neurological care needs are increasing with the aging population

Brain Scientific (OTCQB: BRSF) has created a solution that makes EEG technology accessible. The Company’s neurotech ecosystem is making it possible for all hospitals to perform EEG tests efficiently. The technology is simple to use. Neurologists are given the resources necessary to automate the tedious tasks and focus their energy on the patient while simultaneously broadening their range of impact. BRSF’s ecosystem begins with the disposable and easy-to-apply clinical-grade NeuroCap(TM), patented and FDA-cleared, that comes in small, medium, large, and pediatric (extra small) sizes. This disposable headset comes equipped with 22 pre-gelled electrodes that eliminate the task of head measurement and electrode placement. This significantly reduces the amount of time needed to set up, limiting the amount of contact between the patient and the medical professional applying the headset. In addition, because it is disposable and does not need to be painstakingly cleaned before moving on to the next patient, more EEGs can be administered, and the risk of cross-infection is significantly reduced. The NeuroEEG(TM), patented and FDA cleared, is a portable and wireless EEG amplifier that fits into the palm of your hand and is used to monitor electrical brain activity. By making EEG technology more available, BRSF has created a time-saving and cost-effective solution for hospitals while simultaneously meeting the growing need for additional neurological care of the communities those hospitals serve. Emergency departments and hospitals are not the only markets that require brain monitoring devices. Improved technology is necessary in specialized niche markets that address Alzheimer’s disease, traumatic brain injury, depression, epilepsy, ADHD, stroke, sleep disorders, dementia, migraine, and more. It’s estimated that the U.S. medical device industry will grow to $208 billion by 2023, and BRSF is ready to meet that increasing need. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF